The earnings miss and widening loss are near-term negatives, but the stock's direction will hinge on upcoming regulatory catalysts for AMT-130 (FDA Type B meeting in Q2, MHRA MAA submission in Q3). Traders should watch for any FDA feedback that could derail or accelerate the path to approval, as well as the four-year AMT-130 data analysis expected in Q3 2026.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $21.16entry
- T+1 · 7mo ago +7.84%α +6.46% · $22.82
- T+5 · 6mo ago +30.62%α +28.64% · $27.64
- T+20 · 6mo ago +26.46%α +21.51% · $26.76
- T+60 · 4mo ago +99.39%α +96.65% · $42.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and revenue of $3.6M, below the $4.5M consensus. The net loss widened to $53.5M from $43.6M a year ago, driven by a $9.2M increase in SG&A expenses. The stock may react negatively to the earnings miss and widening loss, though the company's strong cash position ($586.6M) and upcoming regulatory milestones for AMT-130 provide some offset.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.85 missed consensus of -$0.75 by 13.3%
- Q1 2026 revenue of $3.6M missed consensus of $4.5M by 20%
- Net loss widened to $53.5M from $43.6M in Q1 2025
- SG&A expenses surged 84% to $20.1M from $10.9M a year ago
- Cash, cash equivalents and investment securities of $586.6M as of March 31, 2026
- Cash runway into second half of 2029
- FDA Type B meeting for AMT-130 scheduled for Q2 2026
- MAA submission for AMT-130 to UK MHRA expected in Q3 2026
- AMT-260 Phase I/IIa data from first cohort expected at Epilepsy Foundation Pipeline Conference June 18-19, 2026
- AMT-162 development discontinued after dose-limiting toxicity
Financial Impact
EPS miss of 13.3% and revenue miss of 20% vs consensus; net loss widened by $9.9M YoY
Risk Factors
- FDA may not agree that Phase I/II data plus external control are sufficient for BLA, requiring a new costly trial
- SG&A expense growth may continue as the company builds commercial infrastructure for AMT-130
- AMT-260 and AMT-191 clinical data may disappoint
- Liability from royalty financing agreement of $482.3M could pressure future cash flows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287519 |
Track record
38 reports on QURE
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers